+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis

Journal of Cancer Research and Clinical Oncology 139(4): 653-659

This meta-analysis was designed to compare the effectiveness of the combination of transarterial chemoembolization (TACE) and percutaneous radiofrequency ablation (PRFA) with that of TACE and PRFA monotherapy in hepatocellular carcinoma (HCC). Randomized controlled trials were searched using various databases, and six studies were revealed on comparing TACE plus PRFA with TACE and/or PRFA alone for the treatment for HCC. Overall survival rate and recurrence-free survival rate were analyzed and compared. All statistic analyses were conducted using Review Manager (version 4.2.2.) from the Cochrane collaboration. Meta-analysis data revealed that TACE plus PRFA had significantly better effectiveness on 1- and 3-year overall survival rate(odds ratio [OR] 1-year = 4.61, 95 % confidence interval [95 % CI] 2.26-9.42, P < 0.0001; OR 3-year = 2.79, 95 % CI 1.69-4.61, P < 0.0001) and 3-year recurrence-free survival rate ([OR] 3-year = 3.00, [95 % CI] 1.75-5.13, P < 0.0001) than that of TACE and/or PRFA alone treatment. There was no significant difference between the combined therapy and monotherapy on 1-year recurrence-free survival rate ([OR] 1-year = 1.55, [95 % CI] 0.91-2.65, P = 0.11). The data of our study indicate that the combination of TACE and PRFA has better effectiveness than that of TACE and PRFA monotherapy in the treatment for patients with HCC.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036701900

Download citation: RISBibTeXText

PMID: 23292073

DOI: 10.1007/s00432-012-1369-x

Related references

Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdominal Radiology 2019, 2019

Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center. Cardiovascular and Interventional Radiology 40(11): 1748-1755, 2017

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget 8(17): 29416-29427, 2017

Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis. Hepato-Gastroenterology 62(139): 710-714, 2016

Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. Journal of Gastroenterology and Hepatology 28(3): 456-463, 2013

Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (Tace) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) for Treatment of Intermediate Hepatocellular Carcinoma. Gastroenterology 144(5): S-722, 2013

P.13.7 Comparison Between Transcatheter Arterial Chemoembolization (Tace) And Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) For Treatment Of Intermediate Hepatocellular Carcinoma (Hcc). Digestive and Liver Disease 45: S183-S184, 2013

Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). European Radiology 16(3): 661-669, 2005

Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention 17(9): 4349-4352, 2016

Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. Plos One 9(6): E100305, 2015

S1885 Combined Transarterial Chemoembolization (Tace) and Percutaneous Local Ablation Therapy for Advanced Hepatocellular Carcinoma (Hcc). Gastroenterology 138(5): S-809-S-810, 2010

Combined treatment by trans-arterial chemoembolization (TACE) and us-guided percutaneous radiofrequency termal ablation (RF) of medium large hepatocellular carcinoma (HCC). Journal of Hepatology 34(Supp-S1): 101-102, 2001

Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Journal of Huazhong University of Science and Technology. Medical Sciences 34(5): 692-700, 2015

Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatology Research 39(6): 553-562, 2009

Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. International Journal of Clinical and Experimental Medicine 8(7): 10388-10400, 2015